| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6002293 | Thrombosis Research | 2014 | 29 Pages |
Abstract
Apixaban was found to be a cost-effective alternative to warfarin and aspirin for stroke prevention in patients with AF in Sweden.
Keywords
EQ-5DCEACSwedish KronorSEKNVAFICERQALYCost-effectiveness acceptability curveNOACINRTTROACEuroQol 5 DimensionsApixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial FibrillationapixabanARISTOTLEAspirinSystemic embolismMyocardial infarctionCost-effectivenessIntracranial haemorrhageGastrointestinalTime in therapeutic rangequality-adjusted life yearoral anticoagulantnovel oral anticoagulantconfidence intervalAtrial fibrillationnon-valvular atrial fibrillationcardiovascularICHhazard ratiointernational normalised ratioIncremental cost-effectiveness ratioWarfarin
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Tereza Lanitis, Thitima Kongnakorn, Lena Jacobson, Anna De Geer,